How to Help Your Patients Save Money on Serevent: A Provider's Guide to Savings Programs

Serevent Diskus (salmeterol xinafoate) remains brand-only with no FDA-approved generic as of 2026, creating significant cost barriers for patients. Retail pricing of $420–$557 per inhaler puts it out of reach for uninsured and underinsured patients, while insurance formulary placement frequently results in high copays or prior authorization requirements for commercially insured patients. This guide outlines every savings mechanism available — and how your practice can efficiently connect patients to them.

Understanding the Cost Landscape for Serevent in 2026

Providers need to understand the full pricing picture to counsel patients effectively:

Retail cash price: $420–$557 per 60-inhalation inhaler (30-day supply)

Insurance tier: Typically Tier 3 (non-preferred brand) on most commercial formularies — results in copays of $50–$150+ per fill depending on plan design

With GSK $35 coupon: $35 per fill (commercially insured only)

With GoodRx Gold: ~$406 per fill (no insurance)

With SingleCare: ~$378 per fill (no insurance)

With GSK Access PAP: No cost (qualifying uninsured/underinsured patients)

Program 1: GSK 'Pay No More Than $35' Coupon

This is the most impactful savings tool for your commercially insured patients. GSK's coupon caps out-of-pocket cost at $35/month for Serevent Diskus.

Eligibility criteria:

Must have active commercial (private) health insurance

Must NOT be enrolled in Medicare Part A, B, or D; Medicaid; TRICARE; or other federal/state programs

Must NOT be subject to accumulator adjustment or co-pay maximizer programs (or check with GSK for guidance)

How patients get it: Print or download at gskforyou.com — no enrollment required. Coupon is presented at the pharmacy at time of fill. Your office doesn't need to do anything special.

Program 2: GSK Access Patient Assistance Program (PAP)

For uninsured and underinsured patients who cannot afford Serevent, the GSK Access PAP can provide the medication at no cost.

Key details:

Eligibility: Patients without insurance and with limited incomes generally qualify. Unlike the commercial coupon, this program CAN serve Medicare and government-insured patients who meet income criteria.

Application: Available at gsk-access.com or by calling 1-866-728-4368. Applications require income documentation and your practice's signature on the prescription portion.

Delivery: Approved patients receive Serevent Diskus by mail. Processing time is typically 2–4 weeks for new applications.

Practice tip: Consider having your staff familiar with the online enrollment process. The application can be submitted electronically or by fax. Pre-signing an attestation form for qualifying patients significantly reduces processing time.

Program 3: Medicare Low-Income Subsidy (LIS/Extra Help)

For Medicare patients who don't qualify for the commercial coupon, the Part D Low-Income Subsidy (LIS) program — also called Extra Help — can dramatically reduce prescription costs. Patients with LIS typically pay $0–$11.20 for covered drugs (2026 amounts), depending on their LIS level.

Patients can apply for LIS through the Social Security Administration (SSA) at ssa.gov or by calling 1-800-772-1213. Eligibility is based on income and assets. If your patient is Medicare-eligible and struggling with medication costs, screening for LIS eligibility is high-value.

Prior Authorization: When to Push Back and What to Document

Many commercial plans require prior authorization for Serevent due to its non-preferred status and the availability of combination ICS/LABA alternatives. For appropriate patients, prior authorization is worth pursuing. Document:

Clinical indication: COPD (ICS-free LABA preferable), asthma with specific ICS requirements, EIB prevention

Prior trial and failure (or contraindication to) combination ICS/LABA alternatives, if step therapy was required

Pulmonary function data (FEV1, FVC, DLCO if available) supporting the diagnosis

Any hospitalization or ER visit history related to poor asthma/COPD control

When a Switch Is More Cost-Effective Than Savings Programs

For some patients, switching to a clinically equivalent but cheaper alternative is more sustainable than navigating multiple savings programs. Cost comparison:

Generic budesonide/formoterol (Symbicort generic): $30–$80 with coupons. Most cost-accessible ICS/LABA. Formoterol has faster onset than salmeterol.

Wixela Inhub (generic fluticasone/salmeterol): $60–$225 with coupons. Contains same LABA as Serevent. Good choice when salmeterol specifically is preferred.

Formoterol (Foradil): Standalone LABA, may be more formulary-accessible. Faster onset. Approved for asthma (with ICS) and COPD.

Helping Patients Find Serevent in Stock

Even when cost is resolved, patients may still have difficulty finding a pharmacy with Serevent in stock. Direct them to medfinder for Providers. medfinder calls pharmacies near the patient and finds which ones can fill the prescription, then texts results to the patient. This is especially helpful for Serevent, which some pharmacies only order on demand.

Quick Reference: Savings Decision Tree

Has commercial insurance? → GSK $35 coupon (gskforyou.com). Check for accumulator programs.

On Medicare with low income? → Screen for LIS/Extra Help (SSA). May also qualify for GSK Access PAP.

Uninsured or underinsured? → GSK Access PAP (gsk-access.com, 1-866-728-4368). Also: GoodRx Gold (~$406) or SingleCare (~$378).

Nothing works or clinical switch is appropriate? → Generic budesonide/formoterol or Wixela Inhub. Submit PA if standalone salmeterol is clinically preferred.

For a broader clinical briefing on the Serevent availability landscape and formulary alternatives, see: Serevent Shortage: What Providers Need to Know in 2026.